Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome

Medical Principles and Practice

Volumn 21, Issue 2, 2012, Pages 134-138

  Kotani, Kazuhiko ^a,b   Sakane, Naoki ^a   Taniguchi, Nobuyuki ^b  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Intestinal cholesterol transporter inhibitor; Remnant metabolism; Remnant like particle cholesterol

Indexed keywords

CHOLESTEROL; EZETIMIBE; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REMNANT LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLIC SYNDROME X; MONOTHERAPY; SMOKING HABIT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; TRIGLYCERIDES;

EID: 84857359459     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000332436     Document Type: Article

References (29)

1. Gupta A, Gupta V: Metabolic syndrome: What are the risks for humans? Biosci Trends 2010; 4: 204-212.
2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ: The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132.
3. Dagogo-Jack S, Egbuonu N, Edeoga C: Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. Med Princ Pract 2010; 19: 167-175.
4. Nakamura T, Takano H, Umetani K, Kawabata K, Obata JE, Kitta Y, Kodama Y, Mende A, Ichigi Y, Fujioka D, Saito Y, Kugiyama K: Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005; 181: 321-327. (Pubitemid 41019613)
5. Nakajima K, Nakano T, Tanaka A: The oxidative modification hypothesis of atherosclerosis: The comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006; 367: 36-47.
6. Nakamura T, Obata JE, Takano H, Kawabata K, Sano K, Kobayashi T, Fujioka D, Saito Y, Yano T, Kugiyama K: High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. Atherosclerosis 2009; 202: 234-240.
7. Chan DC, Watts GF, Barrett PH, O'Neill FH, Redgrave TG, Thompson GR: Relationships between cholesterol homoeostasis and triacylglycerol-rich lipoprotein remnant metabolism in the metabolic syndrome. Clin Sci 2003; 104: 383-388. (Pubitemid 36458064)
8. Satoh A, Adachi H, Tsuruta M, Hirai Y, Hiratsuka A, Enomoto M, Furuki K, Hino A, Takeuchi T, Imaizumi T: High plasma level of remnant-like particle cholesterol in the metabolic syndrome. Diabetes Care 2005; 28: 2514-2518. (Pubitemid 41384303)
9. Gylling H, Miettinen TA: Cholesterol absorption: Influence of body weight and the role of plant sterols. Curr Atheroscler Rep 2005; 7: 466-471. (Pubitemid 43033773)
10. Hoenig MR, Kostner KM, Read SJ, Walker PJ, Atherton JJ: Implications of the obesity epidemic for statin therapy: Shifting cholesterol metabolism to a high synthesis and low dietary absorption state. Endocr Metab Immune Disord Drug Targets 2007; 7: 153-166. (Pubitemid 47499940)
11. Vine DF, Takechi R, Russell JC, Proctor SD: Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: Increased atherogenicity for the metabolic syndrome. Atherosclerosis 2007; 190: 282-290. (Pubitemid 46074043)
12. Adiels M, Olofsson SO, Taskinen MR, Borén J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1225-1236.
13. Vine DF, Glimm DR, Proctor SD: Intestinal lipid transport and chylomicron production: Possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atheroscler Suppl 2008; 9: 69-76.
14. Lioudaki E, Ganotakis ES, Mikhailidis DP: Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 2011; 9: 62-86.
15. Betters JL, Yu L: NPC1L1 and cholesterol transport. FEBS Lett 2010; 584: 2740-2747.
16. Sandoval JC, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R, Yuasa-Kawase M, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Ohama T, Matsuyama A, Nishida M, Ishigami M, Komuro I, Yamashita S: Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscler Thromb 2010; 17: 914-924.
17. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL: The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009; 202: 216-224.
18. Masuda D, Nakagawa-Toyama Y, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Sandoval JC, Ohama T, Nishida M, Ishigami M, Yamashita S: Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009; 39: 689-698.
19. Miyashita Y, Endo K, Saiki A, Ban N, Nagumo A, Yamaguchi T, Kawana H, Nagayama D, Ohira M, Oyama T, Shirai K: Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2010; 17: 1070-1076.
20. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A; Study Investigators: Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: A prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs 2009; 9: 91-101.
21. Nozue T, Michishita I, Mizuguchi I: Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized lowdensity lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 2010; 17: 37-44.
22. Hirano T, Nohtomi K, Nakanishi N, Watanabe T, Hyodo T, Taira T: Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients. Clin Nephrol 2010; 74: 282-287.
23. Expert Panel on detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
24. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity: New criteria for 'obesity disease' in Japan. Circ J 2002; 66: 987-992.
25. Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S, Yamamura T: Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem 2007; 53: 2128-2135. (Pubitemid 350197296)
26. Tenenbaum A, Fisman EZ, Motro M, Adler Y: Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins. Cardiovasc Diabetol 2006; 5: 20.
27. Bass A, Hinderliter AL, Lee CR: The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. Ann Pharmacother 2009; 43: 2021-2030.
28. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M: Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007; 581: 5664-5670. (Pubitemid 350179776)
29. Fukuda M, Nakamura T, Kataoka K, Nako H, Tokutomi Y, Dong YF, Yasuda O, Ogawa H, Kim-Mitsuyama S: Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. J Pharmacol Exp Ther 2010; 335: 70-75.